GDR Stock Overview
A molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
genedrive plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.025 |
| 52 Week High | UK£0.12 |
| 52 Week Low | UK£0.014 |
| Beta | -0.12 |
| 11 Month Change | -4.85% |
| 3 Month Change | -10.91% |
| 1 Year Change | -67.33% |
| 33 Year Change | -86.00% |
| 5 Year Change | -88.60% |
| Change since IPO | -98.63% |
Recent News & Updates
Recent updates
Is genedrive (LON:GDR) In A Good Position To Invest In Growth?
Mar 08
Here's Why We're Watching genedrive's (LON:GDR) Cash Burn Situation
Jul 11We're A Little Worried About genedrive's (LON:GDR) Cash Burn Rate
Aug 30Here's Why genedrive (LON:GDR) Must Use Its Cash Wisely
May 17Is genedrive's (LON:GDR) Share Price Gain Of 252% Well Earned?
Jan 29
Shareholder Returns
| GDR | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 2.1% | -12.5% | 0.7% |
| 1Y | -67.3% | -31.5% | 6.1% |
Return vs Industry: GDR underperformed the UK Life Sciences industry which returned -31.5% over the past year.
Return vs Market: GDR underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| GDR volatility | |
|---|---|
| GDR Average Weekly Movement | 19.1% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GDR's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: GDR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 43 | Gino Miele | www.genedriveplc.com |
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.
genedrive plc Fundamentals Summary
| GDR fundamental statistics | |
|---|---|
| Market cap | UK£13.04m |
| Earnings (TTM) | -UK£5.00m |
| Revenue (TTM) | UK£272.00k |
48.9x
P/S Ratio-2.7x
P/E RatioIs GDR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GDR income statement (TTM) | |
|---|---|
| Revenue | UK£272.00k |
| Cost of Revenue | UK£3.81m |
| Gross Profit | -UK£3.54m |
| Other Expenses | UK£1.46m |
| Earnings | -UK£5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0092 |
| Gross Margin | -1,301.47% |
| Net Profit Margin | -1,837.50% |
| Debt/Equity Ratio | 0% |
How did GDR perform over the long term?
See historical performance and comparison